US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Exact Sciences Corp.

< Previous 1 2 Next >
News headline image
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Stockholders Approve Acquisition by Abbott
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences to Participate in November Investor Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces Third Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Schedules Third Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences to Participate in September Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces Second Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Schedules Second Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences to Participate in June Investor Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Earns 2025 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences Announces First-Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
News headline image
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
< Previous 1 2 Next >